Video summary

Dr. Reveals What Really Happened at the FDA Meeting on Peptides

Main summary

Key takeaways

News and Commentary

Overview

A physician-speaker, Dr. Ashley Frazer, describes returning from a two-day FDA meeting in Washington, D.C. The meeting was convened to decide whether seven commonly used peptides should be removed from the FDA’s “do not compound” list, which would otherwise allow physicians to prescribe them legally through 503A compounding pharmacies.

Frazer frames the stakes around public health and product integrity: people often purchase peptides online without oversight, increasing the risk of mislabeled, impure, or incorrectly dosed products—potentially including toxic ones.

Committee vote outcome (passed/failed)

The advisory committee voted:

  • YES (6 of 7 peptides) to allow compounding pharmacy use:
    • BPC-157
    • KPV
    • TB-500
    • MOTS-c
    • Epithalon
    • Semax
  • NO (1 peptide):
    • DSIP

Frazer notes that while the FDA retains final authority, she argues this result is a “win,” because advisory committee majorities are rarely overridden in the FDA’s final rulemaking.

Main critique: the FDA’s presentation and preparedness

Frazer’s central contention is that the FDA did not conduct or present the kind of evidence-based, thorough review she expected. She claims:

  • FDA briefings were unfavorable going into the meeting, but she anticipated a more substantive, “adult” scientific/regulatory discussion.
  • During questioning, FDA representatives appeared:
    • unprepared
    • unable to support their positions
    • to have “flailed” when challenged
  • For multiple peptides, the FDA relied on thin or non-representative evidence, while discounting human and real-world submissions.

Specific examples cited as weak or mismatched evidence

Frazer alleges that the FDA’s approach to BPC-157 became a “blueprint” used for other peptides, including patterns such as:

  • Emphasizing limited evidence or evidence she claims had not been fully reviewed.
  • For documents submitted to the docket, she says FDA representatives claimed they did not have time to review them and therefore did not provide them to the committee.
  • For BPC-157, she says the FDA used:
    • a controlled human study but reviewed only the abstract
    • only three FAERS adverse event reports, which she argues is negligible given the likely millions of uses
    • animal studies (dogs/rats) suggesting liver-enzyme and coagulation concerns—while she argues the doses were astronomical compared with real-world dosing

Frazer also alleges similar patterns for other peptides:

  • KPV: dismissal of topical use based on a study involving dead cadaver skin
  • TB-500: reliance on petri-dish/cell studies; she says FDA admitted historical data came from Google searches on anti-doping forums
  • C-Max and Epithalon: she says FDA stated it did not review peer-reviewed clinical research from Europe/Russia because translation costs were prohibitive—while she claims panel members used AI translation tools during the meeting

Core argument about patient safety: avoiding the gray market

Frazer emphasizes that the key question was not simply whether every peptide is proven safe and effective in all respects. Instead, she argues regulators should consider whether a ban would increase or decrease harm.

Her main claim is:

  • Removing peptides from 503A compounding pharmacies does not stop demand; it pushes use into an unregulated gray market, which may be more dangerous.

She says public commenters and some committee physicians repeatedly underscored this point. She also highlights a physician’s voting statement reflecting a medical-ethics concern:

If the FDA bans access through legal channels, is that causing greater harm by driving patients to less safe sources?

Bottom line

  • The advisory committee recommended allowing six peptides to be compounded (but not DSIP).
  • Frazer argues the FDA’s case seemed underprepared, relied on limited evidence, and did not sufficiently address the safety implications of enabling or worsening gray-market access.
  • The remaining uncertainty is whether the FDA will align with the committee’s majority vote when issuing the final rule.

Presenters / Contributors

  • Dr. Ashley Frazer (speaker/host)
  • FDA representatives (unnamed in the subtitles)
  • Panel/committee physicians and peptide representatives (unnamed in the subtitles)
  • Public commenters (unnamed in the subtitles)

Original video